Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | PTPRF | P10586 | 2/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ERG | P11308 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397206 | 0.88 | TACR3 (0.45) | CDK5CDK5R1IRAK4CHEK1TACR3 | |
| SCHEMBL7573098 | 0.78 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL7579015 | 0.74 | CTSS (0.44) | CYP3A4 | |
| SCHEMBL13471715 | 0.70 | APP (0.49) | CDK5CDK5R1IRAK4CHEK1TACR3 | |
| SCHEMBL7398285 | 0.69 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL2562713 | 0.69 | IRAK4 (0.56) | CDK5CDK5R1IRAK4CHEK1TACR3 | |
| SCHEMBL2550980 | 0.68 | IRAK4 (0.60) | IRAK4CHEK1TACR3HDAC3HDAC8 | |
| SCHEMBL6789965 | 0.68 | ALDH1A1 (0.40) | — | |
| SCHEMBL4702327 | 0.67 | CTSK (0.47) | — | |
| SCHEMBL2555433 | 0.64 | IRAK4 (0.52) | IRAK4CHEK1APPHDAC8PTPRF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002080920-A1 | ARYLACETAMIDO-KETOBENZOXAZOLE AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020156063-A1 | Arylacetamido-ketobenzoxazole as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002080920-A1 | ARYLACETAMIDO-KETOBENZOXAZOLE AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156063-A1 | Arylacetamido-ketobenzoxazole as cysteine protease inhibitors | SERPINB1, SPINT2, PRSS1 | CDK5 648/4885CDK5R1 626/4885IRAK4 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.